"We are encouraged by the Phase I/II interim data showing AZD1222 was capable of generating a rapid antibody and T-cell response against SARS-CoV-2". The results provide data from a wider group of participants than their phase 1 trial, including a small sub-group of participants aged over 55 years and older, and will inform phase 3 trials of the vaccine.
"The fact remains we may never get a vaccine and if we do get one, we have to be prepared that it may not be a vaccine which prevents getting the virus, but rather one that reduces symptoms", she said. However, we need more research before we can confirm that the vaccine effectively protects against SARS-CoV-2 infection., and on how all protection lasts.
Medical journal The Lancet has finally published the results of the Phase 1/2 human trial of the experimental shot, detailing that it generates a strong dual immune response against the novel coronavirus disease, without any major side-effects.
A coronavirus vaccine being developed by Britain's University of Oxford with pharmaceutical giant AstraZeneca appears to be safe and to produce immunity, researchers say.
Samples from the coronavirus vaccine trials are handled inside the Oxford Vaccine Group laboratory in Oxford, England, on June 25, 2020.
"Tomorrow. Vaccines. Just saying", Richard Horton, Editor-in-Chief of The Lancet, said in a tweet on Sunday. The vaccine combines genetic material from the coronavirus with a modified adenovirus that is known to cause infections in chimpanzees. While the results declared today are from phase one of the trials, phase two testing is already underway in the United Kingdom and phase three testing on volunteers in Brazil is also taking place.
"There's increasing evidence that having a T-cell response as well as antibodies could be very important in controlling COVID-19", Hill said.
While the Oxford vaccine has been determined to be safe thus far, it does have a common side effect of those receiving doses developing either fever or headache - however both are low grade and can be treated with over the counter medicine. Therefore, it immediately jumped into the fray to develop a COVID-19 vaccine as soon as it saw the outbreak. "An additional dose may be needed to induce a stronger immune response in the elderly population, but more research is being done to assess this".
Scientists at Oxford have said their experimental vaccine has been shown to prompt a protective immune response against Covid-19 in hundreds of people who took it.
But questions remain about how long an immune response will last and how the vaccines will impact older populations, people with particular health conditions that put them at risk, and racial and ethnic groups more severely affected by Covid-19, they said.
Lilly Asia Ventures, backed by USA drugmaker Eli Lilly and Co, is CanSino's top shareholder, according to Refinitiv data.
The release also notes that there were some local reactions and mild to moderate adverse events, including some with flu-like symptoms and injection site reactions. Pfizer and BioNTech have said they expect to begin a trial later this month with up to 30,000 subjects with the aim of demonstrating vaccine efficacy.